Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.
about
Cardiovascular pharmacogenomics: current status and future directionsPharmGKB summary: very important pharmacogene information for CYP4F2Genotype and risk of major bleeding during warfarin treatment.Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCXAlcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.Integrating electronic health record genotype and phenotype datasets to transform patient careRace-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.Target-specific oral anticoagulants and the hospitalist.Pharmacogenetic Implementation Lessons From the "Real World".Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.Conflicting forces of warfarin and matrix gla protein in the artery wall.Genetic determinants of variability in warfarin response after the dose-titration phase.Dietary Vitamin K and Association with Hepatic Vitamin K Status in a Yup'ik Study Population from Southwestern Alaska.Benefit of pre-emptive pharmacogenetic information on clinical outcome.Anticoagulants: Major Advances Without Clear Consensus.The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
P2860
Q26801183-285BC2C3-4DD6-4B40-8482-A0B906462706Q34664072-8FDFAB6D-4D10-4D1D-846A-4B1DFA7B3A1DQ35006973-41C10EF3-667B-4B37-AD00-5E9F63683189Q35706472-BA0662A6-7837-4C3D-843A-544B6A24F9F9Q35772034-B9796FB5-1496-4AFE-BE40-F1762977B2F3Q36599112-1B13FFE6-2F4A-400C-9FC3-506B67ED980EQ36717256-61E42A03-E6E3-4DB3-B27D-04E95BDF8E63Q37473370-68D821EB-447C-44E7-AAB0-82C8ECCF9626Q37552063-D31F4341-D5C4-4710-B619-1790E32757FCQ38307541-B85B2767-2D1B-4FD1-917C-E46B4B719BC8Q38782191-C2CD742C-DF4A-4B41-9899-7A66D1162735Q38799910-808EA4A9-697A-4A4E-9B37-04B67D04B5CBQ38824447-C595B8C7-7E7C-42C0-A6B4-F2E6CE5E01FAQ43077317-B59BA8A0-69E5-4F08-8177-6FE5EE36CE7BQ43113299-503D8364-C1C6-429A-A99A-9D92E9F04849Q47592472-09AA6568-4907-4EB5-92FD-ACD8AEF6C379Q49612005-1FFA31CA-739B-425E-9D55-F84A7AB885B8Q53064526-9461CFD3-399E-43CB-8E5D-E3A9E872A11EQ53695415-2D349692-9A50-4E7B-9DE4-4BD9A7705524
P2860
Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Genetic risk factors for major ...... rfarin in a community setting.
@ast
Genetic risk factors for major ...... rfarin in a community setting.
@en
type
label
Genetic risk factors for major ...... rfarin in a community setting.
@ast
Genetic risk factors for major ...... rfarin in a community setting.
@en
prefLabel
Genetic risk factors for major ...... rfarin in a community setting.
@ast
Genetic risk factors for major ...... rfarin in a community setting.
@en
P2093
P2860
P356
P1476
Genetic risk factors for major ...... rfarin in a community setting.
@en
P2093
A E Rettie
D Boudreau
D L Veenstra
K E Thummel
P2860
P304
P356
10.1038/CLPT.2014.26
P407
P577
2014-02-06T00:00:00Z